白塞病相关深静脉血栓后综合征的风险与严重程度预测因素
该研究纳入205例有下肢深静脉血栓史的白塞病患者,采用Villalta量表评估血栓后综合征(PTS)并用多普勒超声评估静脉反流、血栓、再通及侧支情况。62%患者存在PTS,18%为重度PTS;免疫抑制治疗可降低重度PTS发生率,抗凝可能通过增加侧支评分影响PTS病程。
要点
- 白塞病合并下肢深静脉血栓患者PTS发生率达62%,重度PTS达18%。
- 免疫抑制治疗(联合或不联合抗凝)可降低重度PTS发生率。
- 干扰素-α较单用硫唑嘌呤再通评分更优,多普勒超声有助预测重度PTS。
核心结论
- 白塞病合并深静脉血栓患者发生重度PTS的风险高,免疫抑制治疗可减少重度PTS的发生。
研究设计与样本
- 纳入205例有下肢深静脉血栓史的白塞病患者(166男、39女,年龄39±9.5岁),用Villalta量表评估PTS,临床评估1周内行多普勒超声检查。
主要发现
- 205例白塞病患者中62%存在PTS,18%为重度PTS。
- PTS患者较无PTS患者反流评分更高(P = .054)、血栓评分更高(P = .02)。
- 抗凝、免疫抑制或抗凝联合免疫抑制治疗均未影响PTS的发生。
- 接受免疫抑制治疗(联合或不联合抗凝)的患者较单用抗凝组重度PTS发生率降低(P = .017)。
- 抗凝联合免疫抑制治疗者侧支评分高于单用免疫抑制者;干扰素-α再通评分优于单用硫唑嘌呤(1.0[范围0-14]vs 2.5[范围0-10];P = .010)。
关键数值与推荐
- PTS存在与严重程度采用Villalta量表评估。
- 多普勒超声在临床评估1周内完成,计算反流、血栓、再通及侧支血管总数。
临床怎么用
- 对白塞病合并下肢深静脉血栓患者应常规行多普勒超声评估以辅助预测重度PTS。
- 免疫抑制治疗(可联合抗凝)可能降低重度PTS风险,干扰素-α可能改善再通。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Deep vein thrombosis (DVT) of the lower extremities is the most common form of vascular involvement in Behçet disease (BD), frequently leading to post-thrombotic syndrome (PTS) as a disabling complication. We have described the clinical characteristics and predictors of PTS presence among patients with BD and lower extremity DVT. We also used venous Doppler ultrasound (US) examinations in our assessment. METHODS: Patients with BD (n = 205; 166 men, 39 women; age 39 ± 9.5 years) and a history of DVT were investigated. The Villalta scale was used to assess the presence and severity of PTS. Doppler US examinations were performed within 1 week of the clinical evaluation. The total number of vessels with reflux, thrombi, recanalization, and collateral vessels were calculated. RESULTS: Of the 205 patients with BD, 62% had had PTS and 18% had had severe PTS. Patients with PTS had had greater reflux (P = .054) and thrombosis (P = .02) scores compared with patients without PTS. Treatment with anticoagulation (AC), immunosuppressive (IS) therapy, or AC combined with IS drugs did not affect the occurrence of PTS. However, patients treated with IS therapy, with or without AC drugs, had a decreased incidence of severe PTS compared with the AC-only group (P = .017). Patients treated with AC plus IS agents also had increased collateral scores compared with patients treated with only IS drugs. Interferon-α use seemed to provide better recanalization scores compared with azathioprine only (1.0 [range, 0-14] vs 2.5 [range, 0-10]; P = .010). CONCLUSIONS: Patients with BD and DVT have a high risk of developing severe PTS. IS treatment decreases the development of severe PTS. AC therapy might influence the course of PTS by increasing the collateral scores, and the use of interferon-α also increased recanalization scores. Routine assessment with Doppler US examinations could be helpful in the prediction of severe PTS.
引用
- Aksoy A, Colak S, Yagiz B, et al. Predictors for the risk and severity of post-thrombotic syndrome in vascular Behçet's disease. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33618067. doi:10.1016/j.jvsv.2021.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。